LLY Stock Recent News

Key Points in This Article: Eli Lilly's (LLY) Zepbound has outshone Novo Nordisk's Wegovy, achieving superior weight-loss results in clinical trials.

The bear case for Eli Lilly has now played out following the reaction to the drugmaker's oral obesity drug trial, an analyst said Wednesday in upgrading the stock.

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year landmark analysis of monarchE, treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit Results reinforce two years of Verzenio plus endocrine therapy as the standard of care in HR+, HER2-, node-positive, early breast cancer at a high risk of recurrence INDIANAPOLIS , Aug. 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial. Treatment with two years of Verzenio plus endocrine therapy (ET) demonstrated a statistically significant and clinically meaningful improvement in OS compared to ET alone in patients with hormone receptor positive (HR+), HER2-, node-positive, high-risk early breast cancer.

Geoff Meacham, Citi Research Managing Director, joins 'Fast Money' to talk competition in the weight loss drug space as Eli Lilly's weight loss pill clears its latest trial.

Major U.S. equities indexes ticked higher as investors looked past concerns about President Donald Trump's effort to remove Federal Reserve Governor Lisa Cook and ahead to Wednesday's Nvidia earnings release.

There's nothing like a successful clinical trial of a high-potential medicine to blast a pharmaceutical company's stock price higher. That was the dynamic behind Eli Lilly's (LLY 5.67%) nearly 6% gain on Tuesday, which easily beat the S&P 500's (^GSPC 0.41%) 0.4% bump higher.

Eli Lilly's Daniel Skovronsky talks the latest orforglipron trial, while UnitedHealth Group CEO Stephen Hemsley is moving quickly on a strategic turnaround.

Eli Lilly and Co. LLY stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio.

Pre-market activity is somewhat better than earlier in the trading session this morning, following a less-bad Durable Goods report for July. We also appear to be bouncing around a bit more in recent trading days after a steadier level following August 2nd lows.

U.S. equities were little changed at midday on limited market-driving corporate earnings news and economic data. The Dow Jones Industrial Average, S&P 500, and Nasdaq all moved by small amounts.